Impact of a spleen registry on optimal post-splenectomy vaccination and care

Human Vaccines & Immunotherapeutics
Sarah LuuIan J Woolley

Abstract

To evaluate quality of patient knowledge and rates of adherence to guidelines amongst splenectomised patients registered to the Spleen Australia registry. Registrants recruited for assessment of residual splenic function post-splenectomy also underwent an assessment of quality of knowledge and a review of their long-term management. Eligible patients were ≥ 18 years of age, registered to the Spleen Australia clinical registry and had been splenectomised at least 1 year prior to their visit. Quality of knowledge was assessed using a validated questionnaire used in similar studies. Receipt of immunisations was validated by record review. Chemoprophylaxis use was self-reported by patients. Adherence was evaluated using Australian guidelines. 77 patients were evaluated for education and adherence. 58% were female, mean age was 58 years, and median duration since splenectomy was 14 years. Most common indications for splenectomy were trauma and haematological conditions. 77% had good knowledge of key educational points to reduce chances of infection. Adherence to immunisations varied with poor adherence to vaccines introduced after 2010. Only 6 patients were adherent to all recommended immunisations. Increasing duration since registr...Continue Reading

References

May 26, 1984·British Medical Journal·A B JohnG R Serjeant
Jan 19, 2002·The Journal of Infection·N BisharatR Raz
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·P K HegartyM P Brady
Jan 28, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Mohsen Saleh El-Alfy, Manal Hamdy El-Sayed
Feb 14, 2007·The Journal of Trauma·Stephanie Mallow CorbettJames C Hebert
Mar 28, 2008·ANZ Journal of Surgery·Jun Chul ChungChang Dae Bae
May 20, 2014·The Medical Journal of Australia·Julie WangKarin Leder
Jul 15, 2015·The Journal of Surgical Research·Gerald P KealeyGraeme Pitcher
Dec 9, 2016·Human Vaccines & Immunotherapeutics·Paolo BonanniAngela Bechini
Dec 16, 2016·Open Forum Infectious Diseases·Alexander David JonesDouglas Bowley
Feb 13, 2017·Journal of Infection and Public Health·Tristan BoamGiuseppe Garcea
Feb 19, 2017·The American Journal of Medicine·Aaron P MitchellDavid L Simel
Jul 20, 2017·Journal of the American Association of Nurse Practitioners·Ruth M CarricoM Cynthia Logsdon
Aug 12, 2017·Internal and Emergency Medicine·Antonio Di SabatinoGino Roberto Corazza
Feb 23, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alicia ArnottAllen C Cheng

❮ Previous
Next ❯

Software Mentioned

SPSS Statistics
MenBV

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.